Broader use of clinical quality registry infrastructure will enhance research‐driven improvements in health care
Clinical or patient registries are organised systems that use “observational study methods to collect uniform data (clinical and other) to evaluate specified outcomes for a population defined by a particular disease, condition, or exposure, and that serves one or more stated scientific, clinical, or policy purposes”.1 Clinical quality registries (CQRs) in Australia refer specifically to clinical registries that regularly provide feedback to participating sites and clinicians regarding performance against clinical quality indicators, with the aim of reducing variation and improving overall patient outcomes.2 They are recognised as important quality improvement initiatives by the Australian Commission on Safety and Quality in Health Care, which released a framework for clinical registries in 2014.2 The Commission has over 90 clinical registries listed in Australia, across diverse clinical areas, surgeries, procedures and devices on its Australian Register of Clinical Registries.3 Nationally, the importance of maximising the impact of CQRs in achieving better health outcomes was recently recognised by the release of the National Clinical Quality Registry and Virtual Registry Strategy.4 However, while CQRs produce technical reports and their data are used for secondary research purposes, their role as an effective research tool in their own right in Australia has received limited specific attention, resulting in a significant unrealised potential in Australian clinical research infrastructure.
- 1. Gliklich RE, Leavy MB, Dreyer NA, editors. Registries for evaluating patient outcomes: a user’s guide. 4th ed. Rockville, MD: Agency for Healthcare Research and Quality, 2020. https://effectivehealthcare.ahrq.gov/products/registries‐guide‐4th‐edition/users‐guide (viewed Aug 2021).
- 2. Australian Commission on Safety and Quality in Health Care. Framework for Australian clinical quality registries. Sydney: ACSQHC, 2014. https://www.safetyandquality.gov.au/sites/default/files/migrated/Framework‐for‐Australian‐Clinical‐Quality‐Registries.pdf (viewed Aug 2021).
- 3. Australian Commission on Safety and Quality in Health Care. Australian Register of Clinical Registries. https://www.safetyandquality.gov.au/australian‐register‐clinical‐registries (viewed Aug 2021).
- 4. Australian Government Department of Health. National Clinical Quality Registry and Virtual Registry Strategy 2020–2030. Canberra: Commonwealth of Australia, 2020. https://www1.health.gov.au/internet/main/publishing.nsf/Content/national_clinical_quality_registry_and_virtual_registry_strategy_2020‐2030 (viewed Aug 2021).
- 5. Karanatsios B, Prang K‐H, Verbunt E, et al. Defining key design elements of registry‐based randomised controlled trials: a scoping review. Trials 2020; 21: 552–574.
- 6. Liu JB, D’Angelica MI, Ko CY. The randomized registry trial: two birds, one stone. Ann Surg 2017; 265: 1064–1065.
- 7. Li G, Sajobi TT, Menon BK, et al. Registry‐based randomized controlled trials ‐ what are the advantages, challenges, and areas for future research? J Clin Epidemiol 2016; 80: 16–24.
- 8. Anderson BR, Gotlieb EG, Hill K, et al. Registry‐based trials: a potential model for cost savings? Cardiol Young 2020; 30: 807–817.
- 9. Mathes T, Buehn S, Prengel P, Pieper D. Registry‐based randomized controlled trials merged the strength of randomized controlled trails and observational studies and give rise to more pragmatic trials. J Clin Epidemiol 2018; 93: 120–127.
- 10. Federal Register of Legislation. National Health (Highly Specialised Drugs Program) Special Arrangement 2021 (PB 27 of 2021). Registered 9 Feb 2022. https://www.legislation.gov.au/Details/F2022C00177 (viewed Feb 2022).
- 11. Therapeutic Goods Administration. How the TGA uses Australian joint replacement registry data. Medical Devices Safety Update 2018; 6(3): 1‐4. https://www.tga.gov.au/sites/default/files/medical‐devices‐safety‐update‐volume‐6‐number‐3‐may‐2018.pdf (viewed Feb 2022).
- 12. Therapeutic Goods Administration. Clinical evidence guidelines: medical devices. Version 3.0, Nov 2021. Canberra: Commonwealth of Australia, 2021. https://www.tga.gov.au/resource/clinical‐evidence‐guidelines‐medical‐devices (viewed Feb 2022).
- 13. European Medicines Agency. Guideline on registry‐based studies. Amsterdam: EMA, 2021. https://www.ema.europa.eu/en/guideline‐registry‐based‐studies‐0 (viewed Dec 2021).
- 14. US Food and Drug Administration. Real‐world evidence. https://www.fda.gov/science‐research/science‐and‐research‐special‐topics/real‐world‐evidence (viewed Aug 2021).
- 15. Kramer DV, Cohen DJ, Parasidis EP. Comparative effectiveness research and cardiovascular device registries: aligning policy and methods. Circ Cardiovasc Qual Outcomes 2021; 14: e007911.
Publication of your online response is subject to the Medical Journal of Australia's editorial discretion. You will be notified by email within five working days should your response be accepted.